Kouvaris John, Kouloulias Vassilis, Kokakis John, Matsopoulos George, Myrsini Balafouta, Vlahos Lambros
Aretaieion University Hospital, Radiology Department, Vas. Sofias Avenue 76, 11528, Athens, Greece.
Eur J Dermatol. 2002 Sep-Oct;12(5):458-62.
To study the impact of amifostine as a cytoprotective agent against acute radiation dermatitis, we reviewed 220 patient records. One hundred cancer patients, with tumors localised in the pelvis (bladder, rectum, prostatic carcinomas, or gynecological cancer), who received radiotherapy and cytoprotective treatment with intravenous infusion of amifostine (group A) were included in this study. Retrospectively, we randomly selected from a database in our hospital 120 historical controls, who received only radiotherapy without cytoprotection (group B). Mean gross dermatitis score (MGDS) was the mean value of recorded acute radiation dermatitis according to common toxicity criteria. In group A versus B patients, a significantly reduced severity of dermatitis (P < 0.001, Fisher's exact test) and significant reduction of MGDS as well as mean interruption treatment time (P < 0.001, Mann-Whitney U test) was observed. The relative risk of the outcome of the two study groups was 0.23 (95% CI: 0.15 to 0.34). The significant dermato-cytoprotective effect of amifostine noticed in our retrospective analysis warrants further investigation with randomised trials.
为研究氨磷汀作为一种细胞保护剂对急性放射性皮炎的影响，我们回顾了220份患者记录。本研究纳入了100例癌症患者，这些患者的肿瘤位于盆腔（膀胱癌、直肠癌、前列腺癌或妇科癌症），接受了放疗及静脉输注氨磷汀的细胞保护治疗（A组）。我们从我院数据库中回顾性随机选取了120例仅接受放疗而未进行细胞保护治疗的历史对照患者（B组）。根据通用毒性标准，平均总体皮炎评分（MGDS）是记录的急性放射性皮炎的平均值。在A组和B组患者中，观察到皮炎严重程度显著降低（P < 0.001，Fisher精确检验），MGDS以及平均治疗中断时间也显著缩短（P < 0.001，Mann-Whitney U检验）。两个研究组结果的相对风险为0.23（95%可信区间：0.15至0.34）。我们在回顾性分析中注意到的氨磷汀显著的皮肤细胞保护作用值得通过随机试验进一步研究。
